Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 11:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 281 matching trials from the live ClinicalTrials.gov search.
Conditions
Prostate Cancer
Interventions
PBRT, PLNRT, AA, LHRH agonist
Radiation · Drug
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
1,792 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
444
States / cities
Birmingham, Alabama • Fairbanks, Alaska • Peoria, Arizona + 316 more
Conditions
Prostate Cancer
Interventions
Metformin, OPC
Drug · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charleston, South Carolina
Completed Phase 3 Interventional Results available

A Study of Degarelix in Patients With Prostate Cancer

NCT00928434
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
59
States / cities
Alexander City, Alabama • Homewood, Alabama • Anaheim, California + 54 more
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
New Brunswick, New Jersey • Portland, Oregon
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Conditions
Prostate Cancer
Interventions
Ibrance, Bicalutamide, Zoladex, Lupron Depot
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Conditions
Prostate Cancer, Insulin Resistance
Interventions
Pioglitazone 30 mg, placebo tablet
Drug
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 85 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
4
States / cities
Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio
Conditions
Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency
Interventions
Pioglitazone 30 mg, Placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Completed Phase 1Phase 2 Interventional Results available

Radiation and Androgen Ablation for Prostate Cancer

NCT01517451
Conditions
Adenocarcinoma of the Prostate
Interventions
Radiation Therapy, Androgen Deprivation Therapy (ADT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland
Conditions
Prostate Cancer
Interventions
dutasteride
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Prostate Cancer
Interventions
STAND-T platform, Survey Administration, Text Messages
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Francisco, California
Conditions
Prostate Cancer
Interventions
myocardial PET imaging
Device
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
51 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Prostate Cancer, Hot Flashes
Interventions
Embr thermal device
Device
Lead sponsor
Embr Labs, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Prostate Cancer Metastatic Disease
Interventions
Hypocaloric anti-inflammatory diet
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Los Angeles, California
Completed Phase 3 Interventional Results available

A Trial of Degarelix in Patients With Prostate Cancer

NCT00946920
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
Conditions
Prostate Cancer
Interventions
walking exercise, weight training, Usual Care
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Metastatic Castrate-sensitive Prostate Cancer
Interventions
Apalutamide, Androgen-deprivation Therapy (ADT)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more
Conditions
Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer
Interventions
Not listed
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Androgen Deprivation Therapy, Prostate Cancer, Prostate Cancer Metastatic
Interventions
Aerobic and resistance exercise, Usual Care
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
zoledronic acid, placebo, androgen deprivation therapy, GnRH agonist, Calcium supplement, Vitamin D
Drug · Other · Dietary Supplement
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
238
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 159 more
Conditions
Prostate Cancer
Interventions
Dexamethasone, Prednisone, docetaxel, Oral antiandrogen, Radiation therapy, LHRH agonist
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2022
U.S. locations
245
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 194 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

De-implementation of Low Value Castration for Men With Prostate Cancer

NCT03579680
Conditions
Cancer of Prostate
Interventions
ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan